Research Article

Nephroprotective Effect of Embryonic Stem Cells Reducing Lipid Peroxidation in Kidney Injury Induced by Cisplatin

Monica Maribel Mata-Miranda,1 Carlos Eduardo Bernal-Barquero,2 Adriana Martínez-Cuazitl,1 Carla Ivonne Guerrero-Robles,1 Virginia Sanchez-Monroy,3 Marlon Rojas-Lopez,4 and Gustavo Jesus Vazquez-Zapien1

1Escuela Militar de Medicina, Centro Militar de Ciencias de la Salud, Secretaria de la Defensa Nacional, Ciudad de México 11200, Mexico
2Facultad de Estudios Superiores de Cuautitlán, Universidad Nacional Autónoma de México, Estado de México 54740, Mexico
3Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Ciudad de México 07320, Mexico
4Centro de Investigación en Biotecnología Aplicada, Instituto Politécnico Nacional, Tlaxcala 90700, Mexico

Correspondence should be addressed to Gustavo Jesus Vazquez-Zapien; gus1202@hotmail.com

Received 21 September 2018; Accepted 3 February 2019; Published 14 March 2019

Academic Editor: Ana Lloret

Copyright © 2019 Monica Maribel Mata-Miranda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. The acute kidney injury (AKI) is characterized by a sudden glomerular filtration reduction, provoking the kidney inability to excrete wastes, such as nitrogen products, losing the homeostasis of fluids and electrolytes. Renal or intrinsic causes of AKI include nephrotoxicity induced by exogenous agents like cisplatin, which causes oxidative stress, being the primary site of injury the proximal tubules of the renal parenchyma. The nephrotoxic AKI alters the biochemical process and leads to apoptosis, culminating in acute tubular necrosis (ATN), characterized morphologically by tubular epithelial cell destruction and clinically by the loss of renal function [1].

1. Introduction

The acute kidney injury (AKI) is characterized by a sudden glomerular filtration reduction, provoking the kidney inability to excrete wastes, such as nitrogen products, losing the homeostasis of fluids and electrolytes. Renal or intrinsic causes of AKI include nephrotoxicity induced by exogenous agents like cisplatin, which causes oxidative stress, being the primary site of injury the proximal tubules of the renal parenchyma. The nephrotoxic AKI alters the biochemical process and leads to apoptosis, culminating in acute tubular necrosis (ATN), characterized morphologically by tubular epithelial cell destruction and clinically by the loss of renal function [1].
Currently, the therapies for AKI involve the use of continuous renal replacement techniques indicated for fluid management, correction of electrolyte and pH problems, and treatments for clinical alterations secondary to uremia [2], but unfortunately, these therapies do not resolve the progressive decrease of renal function.

Although these techniques represent the primary treatment against kidney injury (KI), they are associated with high morbidity and mortality. For this reason, it is necessary to explore new alternative therapies for nephropathic patients, seeking a definitive treatment for KI, which might increase tissue regeneration and renal function [3].

Conceptually, the regenerative medicine is a branch of the medicine associated with therapies that regenerate, repair, or replace tissues or the function of an organ by stimulating and inducing its self-regeneration. Schematically, this discipline includes two therapeutic strategies: one based on tissue engineering and the other focused on the use of living cells or cellular therapies. About cell therapies, grafts or implants of mature cells, progenitor cells, or stem cells (SC) are used in this branch [4].

Embryonic stem cells (ESC) have a high capability for self-renewal and pluripotency, which allow them to give rise more SC and differentiate into the three germ lines and their different cell lineages [5]. These cells are mainly obtained from the internal cell mass of the embryo in the blastocyst stage and are characterized by their ability to retain their proliferative properties in an undifferentiated state for an extended period of in vitro culture and also by their differentiation into diverse types of specialized cells [6], such as pancreatic [7, 8], cardiac [9], nervous [10], and renal cells [5, 11]. In this sense, new therapeutic options for kidney regeneration are widely studied and tested in animal models of KI [12–16].

The cis-diaminodichloroplatinum (II) or cisplatin (CDDP) is an antineoplastic drug used in the treatment of many cancers in solid organs [17]. Clinical studies have shown that approximately one-third of patients who use this antineoplastic suffer kidney damage, showing an increase in blood urea nitrogen and creatinine, as well as electrolyte imbalance [18].

One of the cellular targets of the CDDP is the nuclear DNA, and this genetic material interaction is the reason of its complex nephrotoxicity mechanisms, involving multiple molecules and signaling pathways such as an imbalance in the prooxidant/antioxidant mechanism promoting oxidative/nitrosative stress, triggering cytotoxicity. Among the molecules of interest, p53 is considered an essential mediator of cell death induced by the CDDP. In this regard, several studies have demonstrated that the CDDP-induced nephrotoxicity increases the expression of p53 in proximal tubules, highlighting that the expression of this proapoptotic protein is correlated with the progression of KI [19–21].

Another mechanism that contributes to the nephrotoxicity caused by CDDP is the inhibition of the synthesis of mitochondrial energy compounds. Fatty acids are the primary source of energy of the proximal tubules, which are the primary target of injury and progression of kidney disease caused by CDDP [22]. About this, PDK4 (pyruvate dehydrogenase kinase) gene induces the inhibition of PDC (pyruvate dehydrogenase complex) by phosphorylating its catalytic subunits E1. The PDC catalyzes the conversion of pyruvate to acetyl-CoA, which results in the oxidation of carbohydrates and regulates the entry of these into the tricarboxylic acid cycle [23, 24].

It is important to mention that PDK4 is related with the metabolic dysregulation observed in multiple illnesses such as diabetes type 2 [25, 26], hyperthyroidism [27], cardiomyopathy [28], and KI [22, 29].

On the other hand, CDDP can induce the generation of various reactive oxygen species (ROS) by inactivating the cellular antioxidant system, disrupting the mitochondrial respiratory chain, or interacting with the microsomal cytochrome P450, and it is known that the kidney is especially vulnerable to free radicals, because it is one of the main sites for carrying out oxidative processes. Recently, it has been shown that in high states of oxidative stress, there is an overexpression of the enzyme heme oxygenase-1 (HO-1) in renal tubular cells as a protective response to a diverse range of toxic factors [30, 31].

About HO-1 gene expression, many authors have reported that HO-1 gene expression induction may serve as an immediate nephroprotective response during CDDP treatment. As aforementioned, oxidative pathways participate in CDDP nephrotoxicity, and the inhibition of HO-1 increases the ROS levels; contrary, HO-1 induction protects significantly against CDDP cytotoxicity. In this sense, deficiency or inhibition worsens renal structure and function, and the overexpression of this gene has been associated with nephroprotection. For instance, nephroprotection by global HO-1 induction using chemical inducers and transgenic mice that overexpress HO-1 has been demonstrated in ischemia-reperfusion injury, nephrotoxin-induced kidney injury, acute glomerulonephritis, obstructive nephropathy, and rhabdomyolysis [32, 33].

Considering those mentioned above, therapeutic strategies for KI are needed; in previous works, we have demonstrated the mouse ESC (mESC) differentiation capability [5, 8], as well as their beneficial effects when they are implanted in different animal models [34, 35]. Nevertheless, the spectral analysis by Fourier-transform infrared microspectroscopy (FTIRM) after the implantation of mESC in a murine model of AKI and its correlation with the genetic expression have not been studied to show the nephroprotective effect in the lipid peroxidation. Therefore, this research is aimed at analyzing the mESC nephroprotective effect in AKI induced by CDDP, employing genetic, phenotypic, and spectroscopic techniques.

2. Materials and Methods

2.1. Animal and Study Groups. This experimental work followed the guidelines of the Norma Oficial Mexicana Guide for the use and care of laboratory animals (NOM-062-ZOO-1999) and the disposal of biological residues (NOM-087-ECOL-1995). The animals were males, NIH strain of 2 months old. They were kept in metabolic cages (Allentown Inc.; EcoFlo Rack) in humidity (50-60%) and constant temperature conditions (21 ± 1°C) with a 12 h light/dark cycle and had free access to food and water at all times.
Thirty adult mice were randomly divided into three groups \((n=10)\), the healthy group, isotonic salt solution (ISS) as the control group, and mESC as the experimental group. The healthy group was employed to obtain the normal values of the genetic and protein expression, as well as the spectra of healthy kidney tissue. This group was not manipulated at all. The ISS and mESC groups were subjected to AKI and subsequently received an intraperitoneal (i.p.) injection according to the group that they belonged at 24 h post-AKI. The control group received an i.p. injection of 500 \(\mu\)l of ISS, whereas the experimental group received an i.p. implant of \(1 \times 10^6\) mESC resuspended in 500 \(\mu\)l of ISS. At days 4 and 8 post-AKI, five mice of each group were sacrificed. One kidney of each animal was designated for the obtention of histological sections for histopathological analysis, p53 immunodetection, and FTIRM, and another kidney was used for RNA extraction for the genetic analysis. Renal function was checked prior assays through creatinine serum levels.

### 2.2. Acute Kidney Injury Induction

All members of the control and experimental groups were subjected to AKI employing 18 mg/kg of CDDP (Sigma-Aldrich; P3494), which was administered by an i.p. injection. Serum creatinine was analyzed 48 h prior AKI to prove the health state of all members of the ISS and mESC groups. In the same way, the Ki state was checked at days 4 and 8 post-AKI.

### 2.3. Embryonic Stem Cell Culture

Mouse ESC (ATCC; SCRC-1011) were seeded at a density of 50,000 cells/cm² on a mouse embryonic fibroblast monolayer, employing mESC basal medium (ATCC; SCRR-2010) supplemented with 15% fetal bovine serum, 0.1 mM 2-mercaptoethanol (Invitrogen; 21985023), and 1,000 U/ml mouse leukemia inhibitory factor (Chemicon; ESG1107). The cells were incubated at 37°C in a humidified 5% CO₂ and 95% air incubator. When cultured cells reached 70% confluency, mESC were characterized morphologically and phenotypically by optic microscopy and immunofluorescence technique, as previously reported [5, 8, 35], to confirm the pluripotency state of the cells. After that, doses of \(1 \times 10^6\) mESC were obtained and resuspended in 500 \(\mu\)l of ISS.

### 2.4. Histopathological Analysis

The histopathological analysis was developed at days 4 and 8 post-AKI, sacrificing five mice of each group in each day. As aforementioned, one kidney of each animal was used for this purpose, including the immunocytochemistry and microspectroscopy analysis. For the histopathological and immunocytochemistry analysis, the kidneys were embedded in Tissue-Tek (Sakura; 4583) and frozen; subsequently, three kidney tissue cryosections of 4 \(\mu\)m were obtained from each kidney using a freezing microtome (Ecoshel; ECO-1900). After that, tissue cryosections were fixed in 4% paraformaldehyde for 30 minutes at room temperature and rinsed with phosphate-buffered solution (PBS). Afterward, hematoxylin & eosin staining was performed according to the standard methods. Stained sections were analyzed using a light microscope (Nikon; Eclipse Ti-U) and the software Image-Pro Premier 9.1 (Media Cybernetics).

### 2.5. RT-qPCR Assays

Similar to the histopathological analysis, the genetic examination was developed at days 4 and 8 post-AKI, considering the remaining kidney for this study. Towards this end, total RNA of kidneys mice was isolated using TRIzol reagent (Invitrogen; 15596-018) following the manufacturer’s instructions (Invitrogen; 15596-018); after that, cDNA synthesis was performed using the first-strand cDNA synthesis kit (Invitrogen; 12328-040). RT-qPCR was conducted by using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, USA). At each cycle, accumulation of PCR products was detected by monitoring the increase in fluorescence of the reporter SYBR Green PCR Master Mix (Applied Biosystems; 4309155). Straight away after the amplification, dissociation curves were run and analyzed to ensure the specificity of the PCR product. The relative expression levels were calculated using the CT method, which uses the arithmetic formula \(2^{-\Delta\Delta CT}\). Relative RNA levels of all tested genes were normalized to the \(\beta\)-actin housekeeping gene and were expressed as means ± standard deviation (SD). Primers were designed using the Primer BLAST Software (Table 1).

### 2.6. Immunofluorescence Staining

For the immunodetection of p53, the tissue sections were fixed in 4% paraformaldehyde (Sigma; P6148) for 30 minutes, and then the samples were rinsed with PBS twice. Subsequently, fixed tissues were permeabilized with 0.1% Triton X-100 (Sigma; X-100) in PBS at room temperature for 5 minutes, and after that, samples were rinsed with PBS and incubated with blocking protein (Dako; X0909) for 20 minutes to inhibit nonspecific staining. Immunocytochemistry staining was done using mouse primary antibody anti-p53 (1:200, Santa Cruz Biotechnology; Pab1801:sc-98); anti-p53 was incubated for 60 minutes at room temperature. Subsequently, samples were washed with PBS twice, and the conjugated secondary antibody Alexa Fluor 647 goat anti-mouse (1:200, Abcam; ab150115) was incubated for 45 minutes in darkness. Finally, the samples were washed with PBS and coveredslipped with 10% glycerol. Microscopic observations were performed in fluorescence microscopy (Nikon; Eclipse Ti-U). Three sections of each kidney were analyzed.

| Gene    | Forward 5′-3′ | Reverse 5′-3′ |
|---------|--------------|--------------|
| PDK4    | GAGCTGTTCCTCCCGCTACAG | CGGTACCGCCAGGATGTCAAT |
| HO-1    | CAGAAGAGGCTAAAGACGCC | TCTGACGAAGTGACGCCATC |
| β-Actin | AGAGGGAAATCGTGCGTGAC | AACCCTCGTTGCAAATAGT |
Table 2: Ratio assignment obtained from Fourier-transform infrared microspectroscopy (FTIRM).

| Ratio name             | Chemical description                                                                 | Spectral assignment          |
|------------------------|---------------------------------------------------------------------------------------|------------------------------|
| Protein/lipid          | Amide II bending N-H and stretching vibration C-N (δNH→-C-N)/CH₃ asymmetric stretching vibration (vasCH₃) | 1543 cm⁻¹/2960 cm⁻¹          |
|                        | =CH cis stretching vibration (cisC=C-H)/=CH cis stretching vibration (cisC=C-H)+CH₂ symmetric stretching vibration (vasCH₂)+CH₃ symmetric stretching vibration (vasCH₃)+C=O stretching (νC=O)+CH₂ bending (δCH₂) |                             |
| Olefinic/total lipid   | =CH cis stretching vibration (cisC=C-H)/CH₂ asymmetric stretching vibration (vasCH₂)+CH₃ symmetric stretching vibration (vasCH₃)+C=O stretching (νC=O)+CH₂ bending (δCH₂) | 3013 cm⁻¹/(3013 + 2921 + 2854 + 1746 + 1457 cm⁻¹) |
| Olefinic/total CH₂     | CH₂ asymmetric stretching vibration (vasCH₂)/CH₃ stretching vibration (vasCH₃)            | 3013 cm⁻¹/(2921 + 2854 + 1457 cm⁻¹) |
| CH₂/CH₃                |                                                                                       | 2921 cm⁻¹/2960 cm⁻¹          |
| Lipid peroxidation     | C=O stretching (νC=O)/CH₂ bending (δCH₂)                                                 | 1746 cm⁻¹/1457 cm⁻¹          |

2.7. Fourier-Transform Infrared Microscopy Analysis. To develop the biomolecular analysis through vibrational spectroscopy, three tissue sections of each kidney were analyzed by FTIRM using an FTIR microscope (Jasco; IRT-5200) coupled to an FTIR spectrometer (Jasco; 6600), measuring glomeruli and the tubular system from the cortex and medulla in triplicate. For which purpose, cryosections of 5 μm were obtained and mounted on a gold-coated microscope slide with a gold layer thickness of 100 nm (Aldrich; 643246-5EA). After that, employing a Cassegrain objective of 16x, kidney tissue was focused and dried at room temperature for about 15 minutes to remove excess water, measuring the spectra until the absorption bands related to water were undetectable. Each spectrum was collected in the mid-infrared range (4000-400 cm⁻¹) at a spectral resolution of 4 cm⁻¹ with 120 scans.

2.8. Spectral Analysis. Spectral analysis was performed in the C-H stretching (3025-2800 cm⁻¹) and on the fingerprint (1800-800 cm⁻¹) regions using a Jasco Spectra Manager software. FTIR absorbance spectra were normalized using a standard normal variant (SNV) normalization employing the Unscrambler X software (version 10.3, Camo). All the spectra of each analyzed microstructure (glomeruli and tubular system of the cortex and medulla) were averaged according to the group that they belonged. Then, the second derivative was calculated employing the Savitzky-Golay algorithm with fifteen point windows and the second polynomial order using the Unscrambler X. Thereafter, the second derivative spectra were analyzed in terms of deconvoluted absorption bands to determine the individual vibrational modes that contribute to the FTIR signal by using a best-fit peak fitting routine of Origin software (version 6.0, OriginLab Corporation), based on the Levenberg-Marquardt nonlinear least-squares method, obtaining the Lorentzian curves whose intensities were used to calculate the ratios corresponding to protein/lipid, olefinic/total lipid, olefinic/total CH₂, CH₂/CH₃, and lipid peroxidation described in Table 2. Each spectral peak was manually selected to define the starting condition for the best-fit procedure. Finally, the Unscrambler X was used to perform the principal component analysis (PCA) in the lipid spectral region.

2.9. Statistical Analysis. All data were performed in triplicate, and all experiments were repeated at least three times. Serum creatinine concentrations, gene expression data, the protein fluorescence intensity, and area ratios were presented as mean ± SD. These data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s test to determine any significant differences. p values of less than 0.05 were considered statistically significant.

3. Results

3.1. Serum Biochemical Analysis. As previously mentioned, renal function was checked through creatinine serum levels 48 h prior AKI in the ISS and mESC groups, which exhibited normal values (0.69 ± 0.19 for the ISS group and 0.73 ± 0.17 mg/dl for the mESC group). After that, the creatinine was analyzed on day 4 post-AKI showing a significant increment in the ISS and mESC groups (2.33 ± 0.68 and 1.86 ± 0.53 mg/dl, respectively). Likewise, this metabolite was evaluated at day 8 post-AKI evidencing a decrement (1.62 ± 0.83 for the ISS group and 1.15 ± 0.11 mg/dl for the mESC group) (Figure 1). In the ISS group, a statistical significance was shown at days 4 and 8 post-AKI concerning preinduction values; nevertheless, the mESC group only showed a statistical significance at day 4 post-AKI regarding preinduction values. However, no statistical significance was observed between the ISS and mESC groups.

Once KI was evidenced, histopathological, genetic, phenotypic, and spectroscopic analyses were carried out at days 4 and 8 post-AKI.

3.2. Histopathological Description. Five mice of each group were sacrificed at days 4 and 8 post-AKI, and three kidney tissue sections of each kidney were obtained to analyze the tubular system and glomeruli.

Both groups (the ISS and mESC groups) exhibited a segmental focal glomerulosclerosis (SGF) (1) and interstitial nephritis characterized by inflammatory infiltrated (2), as well as characteristics related to ATN, such as tubular dilatation (3) and diffuse denudation of the tubular cells plugging the tubular lumen (4). Even though these histological changes were observed in both groups, it is worth to
In this research, genes that encode tubular cells (5) and binucleation (6) were also detected. It is important to mention that in both groups at day 8 post-AKI, the expression was lower than that in the mESC group, almost reaching the expression of the healthy group (Figure 3(b)).

3.3. Gene Expression. In this research, genes that encode enzymes involved in the mitochondrial metabolic pathways such as PDK4 and HO-1 were studied in the three groups, considering two measurement times for the ISS and mESC groups at days 4 and 8 post-AKI. Changes in the relative expression by RT-qPCR of the genes mentioned above are summarized in Figure 3.

The results showed that PDK4 gene expression increased up to 47-fold at day 4 in the ISS group with respect to the healthy group; nevertheless, in the mESC group, the expression decreased to 0.01-fold with respect to the healthy group. After that, at day 8 post-AKI, the expression of this gene decreased in the ISS group to 0.7-fold, and in the group treated with mESC, the expression increased to 0.08-fold. It is important to mention that in both groups at day 8 post-AKI, the expression was lower than that in the healthy group (Figure 3(a)).

With respect to HO-1 gene expression at day 4 post-AKI, as observed in PDK4 gene, the expression of this gene also increased up to 115-fold in the ISS group with respect to the healthy group; in the same way, the expression increased in the mESC group to 4-fold in relation to the healthy group. Finally, at day 8 post-AKI, the expression decreased in both groups to 0.4 for the ISS group and to 0.6 for the mESC group, almost reaching the expression of the healthy group (Figure 3(b)).

3.4. Immunodetection of p53. Figure 4 shows the immunodetection of the proapoptotic protein p53 in mouse kidney histological samples, specifically in the proximal tubule region. The expression of the protein p53 at day 4 post-AKI was evidenced in the ISS and mESC groups; however, in the group treated with ISS, this expression was higher, increasing significantly at day 8 post-AKI in the ISS groups with respect to the mESC group, highlighting that a statistical significance was observed in all groups concerning the healthy group and between ISS and mESC groups.

3.5. Fourier-Transform Infrared Microspectroscopy. The averages of the raw and normalized FTIRM spectra of the three groups are shown in Figure 5(a), and the spectral band assignments are summarized in Figure 5(b). Two measurement times for the ISS and mESC groups were considered at days 4 and 8 post-AKI. In the biological fingerprint region (1800-800 cm⁻¹), different representative bands associated to biomolecules are evidenced such as lipids, proteins, carbohydrates, and nucleic acids.

Regarding the fingerprint region, in the spectral interval between 1700 and 1500 cm⁻¹ related to amide I and II groups of the proteins, an increase in the absorption bands in the AKI groups (ISS and mESC) was observed; at day 4 post-AKI, the mESC group exhibited the highest peak intensity at 1656 cm⁻¹ which corresponds to amide I, decreasing at day 8. Nevertheless, in the ISS group, even though an increment in the intensity of this band was observed with respect to the healthy group, it retained almost equal at days 4 and 8 post-AKI. After that, it has shown the following absorption bands at 1457 cm⁻¹, 1340 cm⁻¹, 1238 cm⁻¹, and 1084 cm⁻¹, which are related to CH₂ bending of lipids, collagen, and PO₃⁻ asymmetric and symmetric stretching of phospholipids and nucleic acids, respectively. These bands show high intensity in the ISS group compared to the healthy group, whereas these bands in the mESC group were lower in intensity with respect to the healthy group (Figure 5).

On the other hand, employing the second derivative spectra, the ratios of protein/lipid, olefinic/total lipid, olefinic/total CH₂, CH₂/CH₃, and lipid peroxidation were calculated (Table 2), in order to determine structural and compositional alterations, like lipid concentration, acyl chain flexibility, and lipid peroxidation (Figure 6).

Concerning ratio analysis to evaluate the alterations in lipids, Figure 6(a) shows the protein/lipid ratio. Even though we did not find a statistically significant difference between groups, a ratio decrement in the ISS group at day 4 post-AKI with respect to the healthy group was evidenced, while the mESC group presented higher ratio values at days 4 and 8 post-AKI.

Moreover, Figures 6(b) and 6(c) show the ratios of olefinic/total lipid and olefinic/total CH₂ associated with unsaturated lipid levels. The olefinic/total lipid ratio significantly increased in the ISS group on day 4, decreasing after that on day 8. Nevertheless, in the mESC group, no statistical significance was shown at days 4 and 8 with respect to the healthy group. In the same way, the olefinic/total CH₂ ratio increased in the ISS group at days 4 and 8 post-AKI, finding a statistically significant difference, whereas the mESC group exhibited a decrement in this ratio at day 4 and a slight increment at day 8 post-AKI, highlighting that no statistical significance was observed in this group.
Regarding chain length of lipids, the CH$_2$/CH$_3$ ratio depicted in Figure 6(d) displays that this ratio significantly decreased in the ISS group compared to the healthy group; even though in the mESC group a slight increment was evidenced, the ratios were quite similar to the healthy group.

About lipid peroxidation levels (Figure 6(e)), this ratio increased in the ISS group at day 8 post-AKI, finding a statistically significant difference; nonetheless, the mESC group showed almost the same ratios than the healthy group.

Finally, to correlate the multiple variables obtained from the second derivative spectra, a PCA was performed in the C=O stretching vibration region of lipids region (1752-1731 cm$^{-1}$). In Figure 7, the first three components (PC1, PC2, and PC3) are depicted explaining the 98% of the total variation of the initial data. This analysis revealed that each studied group is separated in a cluster; nonetheless, some data of the healthy and mESC groups at day 8 are correlated in the PC1 and PC3.
4. Discussion

Recent development in cell therapy has demonstrated promising therapeutic effects in KI. Nonetheless, before considering the use of this therapy as a medical option, genetic and biomolecular effects need to be widely studied. For this reason, in this research, we induced AKI in mice employing CDDP, evaluating the mESC implant effects; for which purpose, genetic, phenotypic, and spectroscopic analyses were developed through RT-qPCR, immunocytochemistry, and FTIRM.

Firstly, the KI was confirmed through creatinine serum biochemical analysis. It has been reported that in mice, normal serum creatinine range is $0.630 \pm 0.097$ mg/dl [36], a value that is quite similar to the one obtained in this research before AKI, confirming that all the animals used in this study were healthy. In the same way, similar to Takai et al. who stated values of serum creatinine of $1.72 \pm 0.37$ mg/dl 24 h after CDDP (30 mg/kg) administration in mice [36], we reported values of $2.33 \pm 0.68$ mg/dl in the ISS group and $1.86 \pm 0.53$ mg/dl in the mESC group at day 4 post-AKI, evidencing a remarkable increase of creatinine in both groups; nevertheless, at day 8 post-AKI, a decrement was observed in both groups ($1.62 \pm 0.83$ for the ISS group and $1.15 \pm 0.11$ mg/dl for the mESC group), which is related to a better renal function. Although no statistical significance was observed between the ISS and mESC groups, it is important to mention that neither was between the creatinine values obtained in the mESC group prior AKI and at day 8 post-AKI, which could be related to the initial renal function restoration.

Regarding histopathological analysis, the classification of the World Health Organization for tubulointerstitial diseases considers the etiology, clinical, and histological
characteristics, stating that the CDDP causes ATN [37]. In this respect, our results showed that in both groups (ISS and mESC) at days 4 and 8 post-AKI, histological characteristics related to toxic ATN were observed, such as inflammatory infiltrate, tubular dilatation, and cell desquamation which plugged the tubular lumen (Figure 2). These results agree with Takai et al. who examined mouse kidneys obtained 72 h after CDDP administration, reporting tubular necrosis, dilatation, and hyaline cast [36]. In the same way, agree with Liu et al. who i.p. injected 20 mg/kg of CDDP in mice, reporting severe pathological changes characterized by the distortion of the overall kidney morphology, mainly dilation of renal tubules [38] and also with Ciarimboli et al. who i.p. injected 15 mg/kg of CDDP, reporting 4 days after AKI signs of renal toxicity such as tubular protein casts and vacuolization of proximal tubular cells [39]. Nevertheless, in the mESC group, although intratubular obstruction and inflammatory infiltrate were also observed, the microarchitecture was more preserved, and the tubules were less dilated; in the same way, in the proximal tubular cells, cytoplasmic vacuoles were detected. About this, it is known that cells with reversible lesions can be microscopically identified by the presence of cloudy swelling or hydropic degeneration, being the result of ion and fluid homeostasis that leads to an increase of intracellular water. Besides, binucleation was also shown, representing a consequence of cell injury and a sort of chromosome hyperplasia which is usually seen in regenerating cells. These results suggest that in the mice that received

**Figure 5:** Fourier-transform infrared microspectroscopy (FTIRM) analysis. (a) FTIRM spectra of kidney tissues of healthy mice and mice subjected to acute kidney injury (AKI) treated with isotonic salt solution (ISS) or mouse embryonic stem cells (mESC) at days 4 and 8 post-AKI. Different representative bands associated to biomolecules are evidenced such as lipids, proteins, carbohydrates, and nucleic acids. Each spectrum was collected in the mid-infrared range (4000-400 cm\(^{-1}\)), depicting the average of glomeruli and tubular system from the renal cortex and medulla of each group (\(N = 5\), measured in triplicate). (b) Spectral band assignments.
With respect to RT-qPCR analysis, it is known that the overexpression of \( PDK4 \) leads to the enhancement of fatty acid oxidation (FAO) and decreases the glucose oxidation.

the mESC treatment, the pathological process of nephrotoxicity was stopped in the early stages, promoting a regeneration process [40].
tissue, which also agrees with the histopathological analysis, once the restoration of the microarchtecture in the mESC group was evidenced.

On the other hand, according to the protein analysis, it is well known that p53 is an essential mediator of cell death induced by CDDP, causing cell cycle arrest and apoptosis, as well as activation of oncogenes and hypoxia. There are a large number of studies related to the expression of this proapoptotic protein and nephrotoxicity by CDDP [18, 20, 21]. Our results showed that in the ISS group, the protein P53 was expressed at day 4 post-AKI increasing its expression considerably at day 8 post-AKI. Nevertheless, in the mESC group, this protein was almost undetectable at days 4 and 8 post-AKI. As previously mentioned, mice treated with mESC showed better renal function and less tissue damage, which correlates with a lower immunodetection of this proapoptotic protein (Figure 4).

Concordant with the genetic and phenotypic analysis, the FTIRM spectral analysis supported the results mentioned above. As previously mentioned, structural information of biomolecules such as lipids, proteins (amide I, amide II, and amide III), and nucleic acids was obtained (Figure 5).

With respect to the amide I region (1700-1600 cm⁻¹) related to symmetric stretching vibration of C=O in protein and nucleic acids [43], this band increased in all groups compared with the healthy group; in the ISS group, this increment could be correlated with an augment in protein synthesis, mainly associated with extracellular matrix proteins, related to fibrosis. CDDP inhibits protein synthesis of tubular epithelial cells and triggers proapoptotic molecules associated to inflammatory changes that activate macrophages in response to ROS generation, inducing the expression of inflammatory cytokines such as IL-1, IL-6, TGF-β, and RANTES, contributing to the subsequent fibroproliferative process characterized by overexpression and deposition of collagen types I, III, and IV [44–46]. Even though in the mESC group this band was also high, it is possible that this augmentation is not related to an increment in the production of matrix proteins, once it has been reported that changes in proteins and DNA structure could modify amide I band intensity and SC induce glomerular and tubular cell proliferation, increasing cellular survival by secreting proangiogenic and trophic factors, justifying the augmentation of this band with the kidney cell proliferation, which also agree with the histological results once regeneration data such as binucleation were shown. Moreover, Aggarwal et al. and Eirin et al. have reported that SC reduce fibrosis in murine and porcine models of renal stenosis [47, 48].

As previously mentioned, amide I is associated with collagen, reason by which in this research we analyzed specifically the collagen band at 1340 cm⁻¹, where an increment in the intensity of this band in the ISS group and a reduction in the mESC group were observed that could be related to fibroproliferative process in the ISS group and a fibroprotective effect in the mESC group, agreeing our results with Liu et al. who reported an increase in the band at 1338 cm⁻¹ in liver early fibrosis [49], although it is important to mention that Liu used synchrotron infrared microspectroscopy to characterize the liver fibrosis. Besides, these results also agree

![Figure 7: Principal component analysis (PCA) of lipid region (1752-1731 cm⁻¹). Score plot (PC1 vs. PC2 vs. PC3) from second derivative Fourier-transform infrared microspectroscopy (FTIRM) spectra of healthy mice and mice subjected to acute kidney injury (AKI) treated with isotonic salt solution (ISS) or mouse embryonic stem cells (mESC) at days 4 and 8 post-AKI.](image-url)
with our histopathological results, once glomerulosclerosis was also histologically evidenced.

Additionally, information about the concentration of the biomolecules can be determined from the intensity and the area spectral bands; moreover, the ratios of the band areas provide information about metabolic changes that could correlate to the structure-function relationship [43, 50–52]. In this sense, we analyzed changes in lipid dynamics, such as lipid concentration, acyl chain flexibility, and lipid peroxidation, due to it is reported that biomolecular changes such as lipid alteration, lipid fluidity, protein lipid composition, and the relation between unsaturated/saturated lipids show structure-function relationship, which is related to physiological disorders. Moreover, the band ratios have been used to analyze changes in the cell cycle as well as changes in different metabolic states. In this research, variations in the protein/lipid ratio were observed, which is concordant with the p53 protein expression, results that also agree with those obtained by Yang et al. who reported changes in this ratio due to metabolic changes induced by radiation regulated by p53 [43].

In this regard, as previously mentioned, protein/lipid ratio is related to membrane function. We found a marked decrement of this ratio in the ISS group, especially at day 4 post-AKI (Figure 5(a)), suggesting an increase in lipid content in comparison to protein. Different possible mechanisms could explain these alterations: the oxidative stress induction, mitochondrial dysfunction, and DNA damage altering lipid metabolism and protein content, all those mentioned above induced by CDDP in the proximal tubular cells [53, 54]. CDDP also reduces peroxisomal and mitochondrial FAO metabolism and protein content, all those mentioned above induced by CDDP in the proximal tubular cells [53, 54].

This reduction occurs due to the DNA-binding inhibition with the peroxisome proliferation-activated receptor-α (PPAR-α), decreasing target genes related to FAO and peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1) formation [22, 55]. The increase in lipid content is also related to PDK4 gene overexpression in the ISS group at day 4 post-AKI, and according to Li et al., CDDP induces PDK4 overexpression [22]. In this sense, our results suggest that mESC treatment modulates the protein/lipid ratio and downregulates PDK4 expression, protecting against CDDP nephrotoxicity effects.

Some clinical and experimental studies suggest that there is a relationship between the progression of kidney damage and alterations in lipid metabolism, mainly related to lipoproteins and triglycerides [56, 57]. The above discussion due to the loss of urinary proteins stimulates a greater LDL synthesis [58], and LDL increase in serum (parameter of nephrotic syndrome) may be attributed to the scarce expression of the LDL receptor (LDLR). In fact, some studies state that patients with nephrotic syndrome exhibit an acquired deficiency of LDLR [59].

Besides, lipid-rich environments are more sensitive to free radical damage and oxidation products [60]. Our results suggest that CDDP increased lipid content showing spectroscopic changes, specifically in the ratios of olefinic (unsaturated lipids)/total lipid and olefinic/CH₃, which are directly related to variation in lipid metabolism. We found an increase in these ratios in the ISS group at day 4 post-AKI, suggesting an unsaturated lipid increment (Figures 6(b) and 6(c)). Indeed, these ratios have been studied as markers of unsaturated lipid content, highlighting that membrane phospholipids, specifically in the unsaturated lipids, are sensitive targets of free radical, especially under pathological conditions with elevated lipid peroxidation [52]. Additionally, as previously mentioned, CDDP induces free radical production that can interact with membrane lipids increasing lipid peroxidation [61].

All those as mentioned early indicates that one of the nephrotoxic effects induced by CDDP involves lipid peroxidation. About this, Ognjanović et al. reported an increase in lipid oxidation activity related to KI; in our results, we found that CH₃/CH₂ ratio decreased in the ISS group, and the ratio A1746/A1457 related to lipid peroxidation increased significantly in this group at day 8 (Figures 6(d) and 6(e)). These ratio changes indicate an increment in lipid saturation, corroborating the lipid oxidation as well as the accumulation of long chain length lipids reported by Yan et al. and Genç et al. [43, 51]. Furthermore, these events are related to apoptosis that also is associated with different membrane changes, such as phosphatidylserine exposure, membrane blebbing, and vesicle formation. This apoptotic process also agrees with the histopathological changes and p53 protein overexpression observed in the ISS group. Our results also agree with Yan et al. who demonstrated that the radiation of HCT116 cells induces lipid oxidation, showed by an A1746/A1457 ratio increment. On the other hand, Shiraishi et al. have reported that HO-1 overexpression could be related to a reduction of kidney damage, due to HO-1 degrades heme moiety, acting as scavenging perox radical and inhibiting lipid peroxidation [30, 62], which could explain the low lipid peroxidation ratio in the ISS group at day 4 post-AKI, and an augment of this ratio in this group at day 8 post-AKI, which is also related with HO-1 gene overexpression in the ISS group at day 4 post-AKI. In the same way, the decreased lipid metabolism observed in the mESC group could be related to the low PDK4 expression, which induced pyruvate dehydrogenase kinase activity.

Finally, there are two ways in which SC recognize the site of damage and repair and replace the injured cells: one is a paracrine action mechanism based on the secretion of growth factors and the other is based on their proliferative and differentiation capability [5, 8, 11, 12]. Nevertheless, broader researches are needed in this field, to establish which of the two mechanisms contributes most significantly to the restoration of the damaged tissue and function.

5. Conclusion

According to the obtained results, mESC diminish the CDDP nephrotoxic damage, once the protective effect in the reduction of lipid peroxidation was demonstrated, reflecting a functional and histological restoration. However, it is necessary to study the action and protective mechanisms of the ESC, with the aim to propose new prophylactic strategies in nephrotoxic treatments, expanding the regenerative medicine options.
Data Availability

All the generated data and the analysis developed in this study are included in this article.

Ethical Approval

All procedures involving animals were approved by the Ethics Committee of Escuela Militar de Medicina (CEINV-027).

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

The A022-2017 budgetary program supported this work.

References

[1] R. W. Schrier, W. Wang, B. Poole, and A. Mitra, “Acute renal failure: definitions, diagnosis, pathogenesis, and therapy,” The Journal of Clinical Investigation, vol. 114, no. 1, pp. 5–14, 2004.
[2] P. Fall and H. M. Szerlip, “Continuous renal replacement therapy: cause and treatment of electrolyte complications,” Seminars in Dialysis, vol. 23, no. 6, pp. 581–585, 2010.
[3] M. M. Mata-Miranda, R. J. Delgado-Macuil, M. Rojas-Lopez, R. Martinez-Flores, and G. J. Vazquez-Zapien, “Potential therapeutic strategies of regenerative medicine for renal failure,” Current Stem Cell Research & Therapy, vol. 12, no. 5, pp. 423–431, 2017.
[4] J. R. Lamas López, “Medicina regenerativa aplicada al tratamiento de las patologías musculoesqueléticas,” Reumatología Clínica, vol. 10, no. 3, pp. 139–140, 2014.
[5] M. M. Mata-Miranda, G. J. Vazquez-Zapien, M. Rojas-Lopez, V. Sanchez-Monroy, D. G. Perez-Ishiwara, and R. J. Delgado-Macuil, “Morphological, molecular and FTIR spectroscopic analysis during the differentiation of kidney cells from pluripotent stem cells,” Biological Research, vol. 50, no. 1, p. 14, 2017.
[6] E. Sykova and S. Forostyak, “Stem cells in regenerative medicine,” Laser Therapy, vol. 22, no. 2, pp. 87–92, 2013.
[7] I. S. Schroeder, A. Rolletschek, P. Blysztczuk, G. Kania, and A. M. Wobus, “Differentiation of mouse embryonic stem cells to insulin-producing cells,” Nature Protocols, vol. 1, no. 2, pp. 495–507, 2006.
[8] G. J. Vazquez-Zapien, M. M. Mata-Miranda, V. Sanchez-Monroy, R. J. Delgado-Macuil, D. G. Perez-Ishiwara, and M. Rojas-Lopez, “FTIR spectroscopic and molecular analysis during differentiation of pluripotent stem cells to pancreatic cells,” Stem Cells International, vol. 2016, Article ID 6709714, 10 pages, 2016.
[9] A. Sachinidis, B. K. Fleischmann, E. Kolossov, M. Wartenberg, H. Sauer, and J. Hescheler, “Cardiac specific differentiation of mouse embryonic stem cells,” Cardiovascular Research, vol. 58, no. 2, pp. 278–291, 2003.
[10] S. H. Lee, N. Lumelsky, L. Studer, J. M. Auerbach, and R. D. McKay, “Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells,” Nature Biotechnology, vol. 18, no. 6, pp. 675–679, 2000.
[11] A. Maeshima, M. Nakasatomi, and Y. Nojima, “Regenerative medicine for the kidney: renotrophic factors, renal stem/progenitor cells, and stem cell therapy,” BioMed Research International, vol. 2014, Article ID 959493, 10 pages, 2014.
[12] F. Tögel, Z. Hu, K. Weiss, J. Isaac, C. Lange, and C. Westenfelder, “Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms,” American Journal of Physiology-Renal Physiology, vol. 289, no. 1, pp. F31–F42, 2005.
[13] P. T. Lee, H. H. Lin, S. T. Jiang et al., “Mouse kidney progenitor cells accelerate renal regeneration and prolong survival after ischemic injury,” Stem Cells, vol. 28, no. 3, pp. 573–584, 2010.
[14] A. van Koppen, J. A. Joles, B. W. M. van Balkom et al., “Human embryonic mesenchymal stem-cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease,” PLoS One, vol. 7, no. 6, article e38746, 2012.
[15] A. R. Chade, X. Zhu, R. Lavi et al., “Endothelial progenitor cells restore renal function in chronic experimental renovascular disease,” Circulation, vol. 119, no. 4, pp. 547–557, 2009.
[16] B. Imberti, S. Tomasoni, O. Ciampi et al., “Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury,” Scientific Reports, vol. 5, no. 1, p. 8826, 2015.
[17] R. P. Miller, R. K. Tadagavadi, G. Ramesh, and W. B. Reeves, “Mechanisms of cisplatin nephrotoxicity,” Toxins, vol. 2, no. 11, pp. 2490–2518, 2010.
[18] M. Jiang, X. Yi, S. Hsu, C. Y. Wang, and Z. Dong, “Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity,” American Journal of Physiology-Renal Physiology, vol. 287, no. 6, pp. F1140–F1147, 2004.
[19] Q. Wei, G. Dong, T. Yang, J. Megyesi, P. M. Price, and Z. Dong, “Activation and involvement of p53 in cisplatin-induced nephrotoxicity,” American Journal of Physiology-Renal Physiology, vol. 293, no. 4, pp. F1282–F1291, 2007.
[20] B. S. Cummings and R. G. Schnellmann, “Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways,” The Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 1, pp. 8–17, 2002.
[21] M. Jiang and Z. Dong, “Regulation and pathological role of p53 in cisplatin nephrotoxicity,” The Journal of Pharmacology and Experimental Therapeutics, vol. 327, no. 2, pp. 300–307, 2008.
[22] S. Li, P. Wu, P. Yarlagadda et al., “PPARα ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity,” American Journal of Physiology-Renal Physiology, vol. 286, no. 3, pp. F572–F580, 2004.
[23] J. Koolman and K.-H. Röhm, “Bioquímica humana: texto y atlas,” Médica Panamericana, Madrid, España, 2012.
[24] D. Portilla, “Energy metabolism and cytotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 432–438, 2003.
[25] S. S. Kulkarni, F. Salehzadeh, T. Fritz, J. R. Zierath, A. Krook, and M. E. Osler, “Mitochondrial regulators of fatty acid metabolism reflect metabolic dysfunction in type 2 diabetes mellitus,” Metabolism, vol. 61, no. 2, pp. 175–185, 2012.
[26] R. Tao, X. Xiong, R. A. Harris, M. F. White, and X. C. Dong, “Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes,” PLoS One, vol. 8, no. 8, article e71997, 2013.
[27] M. C. Sugden, H. S. Lall, R. A. Harris, and M. J. Holness, “Selective modification of the pyruvate dehydrogenase kinase isoform profile in skeletal muscle in hyperthyroidism:...
implications for the regulatory impact of glucose on fatty acid oxidation,” *The Journal of Endocrinology*, vol. 167, no. 2, pp. 339–345, 2000.

[28] G. Zhao, N. H. Jeong, S. C. Burgess et al., “Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 294, no. 2, pp. H936–H943, 2008.

[29] C. J. Oh, C. M. Ha, Y. K. Choi et al., “Pyruvate dehydrogenase kinase 4 deficiency attenuates cisplatin-induced acute kidney injury,” *Kidney International*, vol. 91, no. 4, pp. 880–895, 2017.

[30] F. Shiraishi, L. M. Curtis, L. Truong et al., “Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis,” *American Journal of Physiology-Renal Physiology*, vol. 278, no. 5, pp. F726–F736, 2000.

[31] N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms and renoprotective strategies,” *Kidney International*, vol. 73, no. 9, pp. 994–1007, 2008.

[32] S. Bolisetty, A. Traylor, R. Joseph, A. Zarjou, and A.agarwal, “Proximal tubule-targeted heme oxygenase-1 in cisplatin-induced acute kidney injury,” *American Journal of Physiology-Renal Physiology*, vol. 310, no. 5, pp. F385–F394, 2016.

[33] G. J. Schaaf, R. F. M. Maas, E. M. de Groene, and J. Fink-Gremels, “Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells,” *Free Radical Research*, vol. 36, no. 8, pp. 835–843, 2002.

[34] G. J. Vázquez-Zapién, M. E. Ordoñez-Gutiérrez, J. I. Minero-Alfaro, V. H. Guerrero-Guerrerro, I. Mora-Mendoza, and M. M. Mata-Miranda, “Functional and histlogic effects after implanting pluripotent stem cells in a murine model with sphincterotomy,” *Revista de Gastroenterología de México*, 2018.

[35] G. J. Vázquez-Zapién, M. Rojas-López, R. J. Delgado-Macuil, L. R. Martínez-Nava, D. G. Pérez-Ishiwara, and M. M. Mata-Miranda, “Histologic and spectroscopic study of pluripotent stem cells after implant in ocular traumatic injuries in a murine model,” *Stem Cell Research & Therapy*, vol. 5, no. 5, p. 119, 2014.

[36] N. Takai, K. Abe, M. Tonomura et al., “Imaging of reactive oxygen species using [1H]hydroxymethide in mice with cisplatin-induced nephrotoxicity,” *BJMMRI Research*, vol. 5, no. 1, p. 38, 2015.

[37] A. B. Fogo and M. Kashgarian, *Diagnostic Atlas of Renal Graft Biopsy*, Elsevier, Philadelphia, 3rd ed edition, 2017.

[38] M. Liu, Z. Jia, Y. Sun, A. Zhang, and T. Yang, “A H₂S donor GYY4137 exacerbates cisplatin-induced nephrotoxicity in mice,” *Mediators of Inflammation*, vol. 2016, Article ID 8145785, 10 pages, 2016.

[39] G. Ciarimboli, D. Deuster, A. Knief et al., “Organic cation transporter 2 mediates cisplatin-induced ototoxicity and nephrotoxicity and is a target for protective interventions,” *The American Journal of Pathology*, vol. 176, no. 3, pp. 1169–1180, 2010.

[40] M. A. K. Abdellahim and B. M. Jarrar, “Gold nanoparticles induced cloudy swelling to hydronic degeneration, cytoplasmic hyaline vacuolation, polymorphism, binucleation, karyopyknosis, karyolysis, karyorrhexis and necrosis in the liver,” *Lipids in Health and Disease*, vol. 10, no. 1, p. 166, 2011.

[41] S. Zhang, M. W. Huver, R. P. McMillan, M. A. Cline, and E. R. Gilbert, “The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility,” *Nutrition & Metabolism*, vol. 11, no. 1, p. 10, 2014.

[42] M. Orozco-Ibarra and J. Pedriza-Chaverri, “Hemo oxygenase: aspectos básicos y su importancia en el sistema nervioso central,” *Archivos de Neurociencias*, vol. 15, no. 1, pp. 47–55, 2010.

[43] J. Yan, F. Zhang, and Q. Huang, “FTIR microspectroscopy probes particle-radiation effect on HCT116 cells (p53−/−, p53−/+),” *Radiation Research*, vol. 189, no. 2, pp. 156–164, 2018.

[44] F. P. Schena and L. Gesualdo, “Pathogenic mechanisms of diabetic nephropathy,” *Journal of the American Society of Nephrology*, vol. 16, 3_Supplement_1, pp. S30–S33, 2005.

[45] T. Taguchi, A. Nazneen, M. R. Abid, and M. S. Razzaque, “Cisplatin-associated nephrotoxicity and pathological events,” in *Cellular Stress Responses in Renal Diseases*, M. S. Razzaque and T. Taguchi, Eds., pp. 107–121, Karger, Basel, 2005.

[46] E. N. Ghaly, S. W. Gergis, J. N. Aziz, H. D. Yassa, and H. A. R. Hassan, “Role of mesenchymal stem cell therapy in cisplatin-induced nephrotoxicity in adult albino rats: ultrastructural & biochemical study,” *Acta Medica International*, vol. 1, no. 2, pp. 57–66, 2014.

[47] S. Aggarwal, A. Moggio, and B. Bussolati, “Concise review: stem/progenitor cells for renal tissue repair: current knowledge and perspectives,” *Stem Cells Translational Medicine*, vol. 2, no. 12, pp. 1011–1019, 2013.

[48] A. Eirin and L. O. Lerman, “Mesenchymal stem cell treatment for chronic renal failure,” *Stem Cell Research & Therapy*, vol. 5, no. 4, p. 83, 2014.

[49] K. Z. Liu, A. Man, R. A. Shaw, B. Liang, Z. Xu, and Y. Gong, “Molecular determination of liver fibrosis by synchrotron infrared microspectroscopy,” *Biochimica et Biophysica Acta (BBA) - Biomembranes*, vol. 1758, no. 7, pp. 960–967, 2006.

[50] O. Boxkurt, M. Severcan, and F. Severcan, “Diabetes induces compositional, structural and functional alterations on rat skeletal soleus muscle revealed by FTIR spectroscopy: a comparative study with EDL muscle,” *The Analyst*, vol. 135, no. 12, pp. 3110–3119, 2010.

[51] A. Inan Genc, S. Gok, S. Banerjee, and F. Severcan, “Valdecobix recovers the lipid composition, order and dynamics in colon cancer cell lines independent of COX-2 expression: an ATR-FTIR spectroscopy study,” *Journal of the American Society of Nephrology*, vol. 88, no. 6, pp. 1249–1256, 2014.

[52] R. Galgamuwa, K. Hardy, J. E. Dahlstrom et al., “Dichloroacetate prevents cisplatin-induced nephrotoxicity without compromising cisplatin anticancer properties,” *Oxidative Medicine and Cellular Longevity*, vol. 7, no. 4, p. 57, 2017.

[53] Y. Yang, H. Liu, F. Liu, and Z. Dong, “Mitochondrial dysregulation and protection in cisplatin nephrotoxicity,” *Archives of Toxicology*, vol. 88, no. 6, pp. 1249–1256, 2014.

[54] R. Galgamuwa, K. Hardy, J. E. Dahlstrom et al., “Dichloroacetate prevents cisplatin-induced nephrotoxicity without compromising cisplatin anticancer properties,” * journae of the American Society of Nephrology*, vol. 27, no. 11, pp. 3331–3344, 2016.

[55] K. Negishi, E. Noiri, T. Sugaya et al., “A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure,” *Kidney International*, vol. 72, no. 3, pp. 348–358, 2007.

[56] A. Lacquaniti, D. Bolignano, V. Donato, C. Bono, M. R. Fazio, and M. Buemi, “Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment,” *Kidney & Blood Pressure Research*, vol. 33, no. 2, pp. 100–110, 2010.

[57] B. H. C. M. T. Prinsen, M. G. M. de Sain-van der Velden, E. J. P. de Koning, H. A. Koomans, R. Berger, and T. J. Rabelink,
Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms, "Kidney International," vol. 63, pp. S121–S124, 2003.

N. D. Vaziri, T. Sato, and K. Liang, "Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis," *Kidney International*, vol. 63, no. 5, pp. 1756–1763, 2003.

N. D. Vaziri, "Molecular mechanisms of lipid disorders in nephrotic syndrome," *Kidney International*, vol. 63, no. 5, pp. 1964–1976, 2003.

G. Cakmak, L. M. Miller, F. Zorlu, and F. Severcan, "Amifostine, a radioprotectant agent, protects rat brain tissue lipids against ionizing radiation induced damage: an FTIR microspectroscopic imaging study," *Archives of Biochemistry and Biophysics*, vol. 520, no. 2, pp. 67–73, 2012.

B. I. Ognjanović, N. Z. Djordjević, M. M. Matić et al., "Lipid peroxidative damage on cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium," *International Journal of Molecular Sciences*, vol. 13, no. 2, pp. 1790–1803, 2012.

A. Agarwal and H. S. Nick, "Renal response to tissue injury: lessons from heme oxygenase-1 gene ablation and expression," *Journal American Society of Nephrology*, vol. 11, no. 5, pp. 965–973, 2000.